CA2836851C - Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors - Google Patents

Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors Download PDF

Info

Publication number
CA2836851C
CA2836851C CA2836851A CA2836851A CA2836851C CA 2836851 C CA2836851 C CA 2836851C CA 2836851 A CA2836851 A CA 2836851A CA 2836851 A CA2836851 A CA 2836851A CA 2836851 C CA2836851 C CA 2836851C
Authority
CA
Canada
Prior art keywords
alkyl
methyl
compound
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2836851A
Other languages
English (en)
French (fr)
Other versions
CA2836851A1 (en
Inventor
Christopher J. Helal
Thomas Allen Chappie
John M. Humphrey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp SRL filed Critical Pfizer Corp SRL
Publication of CA2836851A1 publication Critical patent/CA2836851A1/en
Application granted granted Critical
Publication of CA2836851C publication Critical patent/CA2836851C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2836851A 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors Expired - Fee Related CA2836851C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494070P 2011-06-07 2011-06-07
US61/494,070 2011-06-07
PCT/IB2012/052627 WO2012168817A1 (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Publications (2)

Publication Number Publication Date
CA2836851A1 CA2836851A1 (en) 2012-12-13
CA2836851C true CA2836851C (en) 2016-06-21

Family

ID=46298646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2836851A Expired - Fee Related CA2836851C (en) 2011-06-07 2012-05-24 Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors

Country Status (11)

Country Link
US (1) US8829010B2 (enExample)
EP (1) EP2718295A1 (enExample)
JP (1) JP2014516074A (enExample)
KR (1) KR101626681B1 (enExample)
CN (1) CN103596956A (enExample)
AU (1) AU2012265970A1 (enExample)
CA (1) CA2836851C (enExample)
IL (1) IL229606A0 (enExample)
MX (1) MX2013014470A (enExample)
SG (1) SG195085A1 (enExample)
WO (1) WO2012168817A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
EP2646448B1 (en) 2010-11-29 2017-08-30 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
WO2014126954A1 (en) * 2013-02-13 2014-08-21 OSI Pharmaceuticals, LLC Regioselective synthesis of substituted pyrimidines
CN104098574A (zh) * 2013-04-12 2014-10-15 苏州科捷生物医药有限公司 氮杂环丁烷取代嘧啶类化合物及其用途
CN105683164A (zh) * 2013-08-20 2016-06-15 杜邦公司 杀真菌吡唑类
EP3087060B1 (en) 2013-12-23 2020-05-13 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as pde2 inhibitors
US9849132B2 (en) 2014-01-08 2017-12-26 Intra-Cellular Therapies, Inc. Products and pharmaceutical compositions
BR112016024713B1 (pt) 2014-04-23 2023-05-02 Dart Neuroscience (Cayman) Ltd Compostos de [1,2,4] triazolo [1,5-a] pirimidin como inibidores de pde2
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
EP3215508A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted 5-methyl-[1, 2, 4]triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
EP3226870B1 (en) 2014-12-06 2019-09-25 Intra-Cellular Therapies, Inc. Organic compounds
MX373320B (es) 2014-12-06 2020-05-04 Intra Cellular Therapies Inc Compuestos inhibidores de pde2.
EP3237401B1 (en) 2014-12-22 2019-03-06 Pfizer Inc Antagonists of prostaglandin ep3 receptor
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
EP3291817B1 (en) * 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
EP3313852B1 (en) * 2015-06-25 2021-01-20 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017000276A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
EP3541784B1 (en) 2016-11-18 2023-09-13 Integrative Research Laboratories Sweden AB Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
CN111447930A (zh) 2017-11-23 2020-07-24 奥斯陆大学医院公司 心动过速的治疗
CA3156783A1 (en) * 2019-11-09 2021-05-14 Yun Jin Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN118903419A (zh) * 2020-02-10 2024-11-08 广州市妇女儿童医疗中心 Pde抑制剂或其盐在制备用于预防和/或治疗胃肠道疾病的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563699C (en) * 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
BRPI0606379A2 (pt) * 2005-01-05 2009-06-23 Nycomed Gmbh triazolftalazinas
WO2006072828A2 (en) 2005-01-07 2006-07-13 Pfizer Products Inc. Heteroaromatic quinoline compounds and their use as pde10 inhibitors
CN102020645B (zh) * 2010-09-30 2012-12-12 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用

Also Published As

Publication number Publication date
US20140080806A1 (en) 2014-03-20
EP2718295A1 (en) 2014-04-16
AU2012265970A1 (en) 2013-11-28
KR20140019466A (ko) 2014-02-14
WO2012168817A1 (en) 2012-12-13
SG195085A1 (en) 2013-12-30
US8829010B2 (en) 2014-09-09
CN103596956A (zh) 2014-02-19
CA2836851A1 (en) 2012-12-13
IL229606A0 (en) 2014-01-30
MX2013014470A (es) 2014-03-21
KR101626681B1 (ko) 2016-06-01
JP2014516074A (ja) 2014-07-07

Similar Documents

Publication Publication Date Title
CA2836851C (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
US8598155B2 (en) Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders
EP3419978B1 (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CA2661334C (en) Pyrimidone compounds as gsk-3 inhibitors
AU2012221828A1 (en) Imidazo[5,1-f][1,2,4]triazines for treatment of neurological disorders
US11345681B1 (en) Inhibitors of fibroblast growth factor receptor kinases
US9422271B2 (en) Pyrimidine compounds as tuberculosis inhibitors
CN115209952B (zh) 经取代的吡唑并嘧啶及其用途
US20230303566A1 (en) Inhibitors of raf kinases
HK1193814A (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
HK40085563A (en) Inhibitors of fibroblast growth factor receptor kinases
NZ613373B2 (en) IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
OA18860A (en) Pyrazolo[1,5-A)pyrazin-4-yl derivatives as Jak-inhibitors
HK1188990A (en) IMIDAZO[5, 1-ƒ][1,2-4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131120

MKLA Lapsed

Effective date: 20180524